- Home
- SUPV vs PHAR Comparison
SUPV vs PHAR Comparison
Compare SUPV & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | PHAR |
|---|---|---|
| Founded | 1887 | 1988 |
| Country | Argentina | Netherlands |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 951.9M | 1.1B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | SUPV | PHAR |
|---|---|---|
| Price | $11.60 | $20.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $13.33 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 1.0M | 28.3K |
| Earning Date | 03-09-2026 | 03-12-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | ★ $396,684,246.00 | $362,274,000.00 |
| Revenue This Year | $12.75 | $25.19 |
| Revenue Next Year | $45.23 | $4.47 |
| P/E Ratio | ★ N/A | $3,528.11 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $4.54 | $7.50 |
| 52 Week High | $17.90 | $20.09 |
Technical Indicators
Market Signals| Indicator | SUPV | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 53.85 | 65.83 |
| Support Level | $10.33 | $17.25 |
| Resistance Level | $12.16 | $20.09 |
| Average True Range (ATR) | 0.65 | 0.62 |
| MACD | -0.03 | 0.19 |
| Stochastic Oscillator | 59.07 | 90.08 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.